October is Breast Cancer Awareness Month, and CURE is here to address some of the most common questions patients have after a ...

There are three main subtypes and they’re grouped by three genetic markers your doctor will look for on a biopsy specimen: ...

Elissa Kalver was diagnosed with HER2-positive metastatic breast cancer at 34. Since then, she has founded a nonprofit and ...

Fact checked by Marley Hall Medically reviewed by Marla Anderson, MD Enhertu is a treatment for HER2-low breast cancer that extends your life expectancy more than chemotherapy. A doctor gives Enhertu ...

For patients with high-risk HER2-positive early breast cancer who have undergone neoadjuvant therapy, treatment with Enhertu ...

Nat Clin Pract Oncol. 2008;5(9):531-542. The authors declared no competing interests. Cite this: The Role of Hormonal Therapy in the Management of Hormonal-Receptor-Positive Breast Cancer With ...

Gerrina Ruiter, MD, PhD, highlights the Beamion LUNG-1 study's impact on treating HER2-mutant non-small cell lung cancer with ...

The once daily oral medication represents an innovative option for breast cancer patients whose disease has progressed ...

In an interview with Targeted Oncology, Gerrina Ruiter, MD, PhD, Netherlands Cancer Institute and study investigator, explains the rationale and design of the Beamion LUNG-1 study, highlights the ...

– Approval is based on Phase III INAVO120 results, showing the Itovebi TM (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the ...

Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of ...